Cholesterol inhibits assembly and oncogenic activation of the EphA2 receptor

  • Commun Biol. 2025 Mar 11;8(1):411. doi: 10.1038/s42003-025-07786-6.
Ryan J Schuck  1 Alyssa E Ward  1 Amita R Sahoo  2 Jennifer A Rybak  3 Robert J Pyron  3 Thomas N Trybala  4 Timothy B Simmons  1 Joshua A Baccile  4 Ioannis Sgouralis  5 Matthias Buck  2 Rajan Lamichhane  6 Francisco N Barrera  7
Affiliations
  • 1. Department of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, USA.
  • 2. Department of Physiology and Biophysics, Case Western Reserve University, School of Medicine, Cleveland, TN, USA.
  • 3. Genome Science and Technology, University of Tennessee, Knoxville, TN, USA.
  • 4. Department of Chemistry, University of Tennessee, Knoxville, TN, USA.
  • 5. Department of Mathematics, University of Tennessee, Knoxville, TN, USA.
  • 6. Department of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, USA. [email protected].
  • 7. Department of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, USA. [email protected].
Abstract

The receptor tyrosine kinase EphA2 drives Cancer malignancy by facilitating metastasis. EphA2 can be found in different self-assembly states: as a monomer, dimer, and oligomer. However, we have a poor understanding regarding which EphA2 state is responsible for driving pro-metastatic signaling. To address this limitation, we have developed SiMPull-POP, a single-molecule method for accurate quantification of membrane protein self-assembly. Our experiments reveal that a reduction of plasma membrane Cholesterol strongly promotes EphA2 self-assembly. Indeed, low Cholesterol levels cause a similar effect to the EphA2 ligand ephrinA1-Fc. These results indicate that Cholesterol inhibits EphA2 assembly. Phosphorylation studies in different cell lines reveal that low Cholesterol increased phospho-serine levels in EphA2, the signature of oncogenic signaling. Investigation of the mechanism that Cholesterol uses to inhibit the assembly and activity of EphA2 indicate an in-trans effect, where EphA2 is phosphorylated by protein kinase A downstream of beta-adrenergic receptor activity, which Cholesterol also inhibits. Our study not only provides new mechanistic insights on EphA2 oncogenic function, but it also suggests that Cholesterol acts as a molecular safeguard mechanism that prevents uncontrolled self-assembly and activation of EphA2.

Products